Arab Finance: The Egyptian International Pharmaceutical Industries Company (EIPICO) reported an 63.6% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first half (H1) of 2023, according to the consolidated financial income statement filed to the Egyptian Exchange (EGX) on August 14^th.

Consolidated net profit attributable to the holding company amounted to EGP 463.410 million in H1 2023, compared to EGP 283.257 million in H1 2022.

Moreover, the company generated consolidated net sales of EGP 2.269 billion in the six-month period ended June 30th, growing from EGP 1.734 billion in the same period last year.

As per EIPICO’s standalone financial income statement, the company achieved a standalone net profit after tax of EGP 468.950 million in H1 2023, up from EGP 297.593 million in the year-ago half.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

ICON’s consolidated profits shrink 40% YoY in 9 months Updated 12/18/2025 10:55:00 AM

Maridive and Oil Services reports 105.5% YoY higher profits in 9 months Updated 12/14/2025 3:11:00 PM

Dice's consolidated profits fall 62.5% YoY in 9 months Updated 12/2/2025 11:15:00 AM

Egypt Duty Free Shops’ consolidated profits drop 18.5% YoY in Q1 FY2025/26 Updated 11/30/2025 2:01:00 PM

IFAP generates 19% YoY lower net profits in Q1 FY2025/26 Updated 11/30/2025 1:42:00 PM